8-K: Passage Bio Reports Positive Interim Data for FTD-GRN Gene Therapy and Provides Financial Update

Passage Bio announced positive interim data from its upliFT-D trial showing consistent elevation of CSF progranulin levels in FTD-GRN patients, along with a financial update indicating a cash runway into Q4 2025.

Summary

• Passage Bio reported its first quarter 2024 financial results and provided an update on its clinical programs.
• The company's upliFT-D trial for FTD-GRN is progressing, with interim data showing that Dose 1 of PBFT02 achieved consistent elevation of cerebrospinal fluid (CSF) progranulin levels at six months post-treatment in two patients.
• Dosing of Cohort 1 in the upliFT-D trial has been completed, and the company is on track to deliver 6-month safety and biomarker data in the second half of 2024.
• Passage Bio plans to continue studying Dose 1 in Cohort 2 of the upliFT-D trial, with dosing expected to begin by the end of the first half of 2024.
• The company has initiated a regulatory process with the FDA to receive feedback on the pathway to treating FTD-C9orf72 patients with PBFT02.
• Passage Bio's cash, cash equivalents, and marketable securities totaled $104.5 million as of March 31, 2024, and the company expects this to fund operations into Q4 2025.
• Research and development expenses were $11.5 million for the quarter ended March 31, 2024, compared to $16.8 million for the same period in 2023.
• General and administrative expenses were $6.5 million for the quarter ended March 31, 2024, compared to $19.0 million for the same period in 2023, which included $11.3 million in non-recurring charges.
• The net loss for the quarter ended March 31, 2024, was $16.7 million, or $0.30 per share, compared to a net loss of $34.3 million, or $0.63 per share, for the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data and a strong cash position. The reduction in net loss and progress in clinical trials contribute to a favorable sentiment.

Positives

• The interim data from the upliFT-D trial shows a consistent progranulin response, which is a positive indicator for the therapy's potential.
• The completion of dosing for Cohort 1 in the upliFT-D trial is a significant milestone.
• The company has a strong cash position that is expected to fund operations into Q4 2025.
• The company is actively engaging with the FDA to expand the use of PBFT02 to treat FTD-C9orf72 patients.
• The company has reduced its net loss compared to the same quarter last year.

Negatives

• The company's cash balance decreased from $167.8 million on March 31, 2023, to $104.5 million on March 31, 2024.
• The company continues to operate at a loss, with a net loss of $16.7 million for the quarter ended March 31, 2024.

Risks

• The company's ability to develop and obtain regulatory approval for its product candidates is subject to risks.
• Clinical trials are subject to risks, including unexpected concerns that may arise from additional data or analysis.
• Regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of the company's drug candidates.
• The company is dependent on collaborators and other third parties for the development and manufacture of product candidates.
• The company is subject to risks associated with current and potential delays, work stoppages, or supply chain disruptions.

Future Outlook

Passage Bio expects to continue advancing its clinical programs, including the upliFT-D trial, and anticipates delivering meaningful data over the next twelve months. The company also plans to explore the benefits of elevated progranulin in multiple adult neurodegenerative diseases and is pursuing outlicensing opportunities for its pediatric clinical-stage programs.

Management Comments

• Will Chou, M.D., president and chief executive officer of Passage Bio, stated that the beginning of 2024 has been marked by strong execution as the company continues to advance its global upliFT-D clinical trial in FTD-GRN.
• Will Chou also mentioned that they are excited to share updated interim data demonstrating continued elevation in CSF progranulin levels at six months after treatment in two patients.

Industry Context

Passage Bio is operating in the competitive field of genetic medicines for neurodegenerative diseases. The company's focus on progranulin-raising therapies for FTD and other conditions aligns with the growing interest in addressing the underlying causes of these diseases. The company is competing with other companies developing gene therapies for similar conditions.

Comparison to Industry Standards

• The consistent elevation of CSF progranulin levels observed in Passage Bio's trial is a positive sign, as many gene therapies struggle to achieve sustained target engagement.
• The company's use of AAV1 vector for delivery of the gene therapy is notable, as it has shown higher levels of CSF progranulin compared to other vectors like AAV5 and AAVhu68 in preclinical studies.
• The company's cash runway into Q4 2025 is relatively strong compared to other clinical-stage biotech companies, providing financial stability for ongoing research and development.
• The reduction in net loss from $34.3 million to $16.7 million year-over-year is a positive trend, indicating improved financial management.

Stakeholder Impact

• Shareholders may view the positive clinical data and extended cash runway favorably.
• Employees may be encouraged by the company's progress and financial stability.
• Patients and families affected by FTD-GRN may be hopeful about the potential of PBFT02.
• The company's suppliers and partners may benefit from the continued operations and development of the company's programs.

Next Steps

• Initiate dosing for Cohort 2 FTD-GRN patients in 1H 2024.
• Report 6-month safety and biomarker data from Cohort 1 patients in 2H 2024.
• Announce 12-month follow-up data from Cohort 1 patients in 1H 2025.
• Report initial safety and biomarker data from Cohort 2 patients in 1H 2025.
• Obtain regulatory feedback on the pathway to treating FTD-C9orf72 and ALS patients with PBFT02 in 2H 2024.

Key Dates

Keywords

FTD-GRN, PBFT02, progranulin, gene therapy, neurodegenerative diseases, clinical trial, FDA, upliFT-D, FTD-C9orf72, biomarkers